Clinical trial
A Prospective, Open-label, Multicenter, Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone(VMP) for Initial Treatment in Patients With Multiple Myeloma Who do Not Undergo Autologous Stem Cell Transplantation
NCT02474563 is registered in ClinicalTrials.gov with Janssen Korea, Ltd., Korea as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Open-label, Multicenter, Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone(VMP) for Initial Treatment in Patients With Multiple Myeloma Who do Not Undergo Autologous Stem Cell Transplantation
- Lead sponsor
- Janssen Korea, Ltd., Korea
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 31, 2011
- Completion date
- May 31, 2014
- Enrollment
- 171 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.